Immunofluorescence Assay Global Market Report 2024

Immunofluorescence assay encompasses both equipment and consumables designed to utilize a technique allowing the visualization of specific proteins and antigens in infected cells. This visualization is achieved through the reaction of these proteins and antigens with specific antibodies, which are chemically conjugated with a fluorescent dye. This laboratory technique is employed in the diagnosis of diseases affecting various organ systems such as the skin, kidney, heart, cilia, and others.

The main types of immunofluorescence assay include direct immunofluorescence and indirect immunofluorescence. Direct immunofluorescence is a laboratory technique specifically used for diagnosing diseases related to the skin, kidney, and other organ systems. In this method, a single antibody directly conjugated to a fluorescent dye is utilized. The diverse range of products in the immunofluorescence assay category includes reagents, instruments, antibodies, kits, consumables, and accessories. These products are employed in the diagnosis of various diseases, including cancer, infectious diseases, autoimmune diseases, among others. Immunofluorescence assay products are utilized by academic and research institutions, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, as well as contract research organizations.

The immunofluorescence assay market research report is one of a series of new reports that provides immunofluorescence assay market statistics, including immunofluorescence assay industry global market size, regional shares, competitors with an immunofluorescence assay market share, detailed immunofluorescence assay market segments, market trends and opportunities, and any further data you may need to thrive in the immunofluorescence assay industry. This immunofluorescence assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunofluorescence assay market size has grown strongly in recent years. It will grow from $3.18 billion in 2023 to $3.43 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth observed in the historical period can be attributed to factors such as an increased focus on disease diagnosis, a rise in research and development activities, an increase in autoimmune diseases, heightened efforts in cancer diagnostics, and an upsurge in virology research.

The immunofluorescence assay market size is expected to see strong growth in the next few years. It will grow to $4.9 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be attributed to factors such as the increasing adoption of personalized medicine, a rise in infectious disease surveillance, an increase in autoimmune disorders, a growing demand for point-of-care testing, and an emphasis on global health preparedness. Key trends expected in the forecast period include the use of multiplexing assays, automation and robotics in laboratory processes, high-content imaging techniques, the utilization of advanced fluorophores for enhanced detection, and the integration of digital pathology in diagnostics.

The robust growth of the immunofluorescence assay market is significantly attributed to the increasing prevalence of chronic diseases. Lifestyle changes, dietary habits, and inadequate weight management contribute to a surge in chronic conditions, with prolonged infections posing a risk of developing cancer. Immunofluorescence assays are witnessing heightened demand for their extensive use in the diagnosis and drug development activities associated with chronic diseases. A study from the Centers for Disease Control and Prevention reveals that around 6 in 10 adults in the USA are affected by chronic diseases, accounting for a substantial annual healthcare cost of $3.8 trillion. Therefore, the escalating prevalence of chronic diseases is anticipated to drive the demand for immunofluorescence assays throughout the forecast period.

The immunofluorescence assay market is poised for further growth due to the increasing demand for personalized medicines. Personalized medicine, utilizing an individual's genetic profile to inform decisions related to disease prevention, diagnosis, and treatment, relies heavily on immunofluorescence assays. These assays play a pivotal role in identifying specific biomarkers crucial for formulating personalized treatment plans. The Personalized Medicine Coalition reports that over 75,000 genetic testing products and 300 personalized medicines will be available for various conditions, including cancer, rare genetic diseases, and chronic and infectious diseases. Consequently, the rising demand for personalized medicines is propelling the growth of the immunofluorescence assay market.

A prominent trend in the immunofluorescence assay market is the emphasis on technological advancements. Companies in this sector are dedicated to developing innovative products with advanced technologies, especially for diagnostic purposes related to emerging viruses like COVID-19. LumiraDx, a UK-based developer of point-of-care diagnostics, received emergency approval for its microfluidic immunofluorescence assay, LumiraDx SARS-CoV-2 Ag Test, designed for the qualitative detection of nucleocapsid protein antigens from nasal swab samples in March 2022.

Major players in the immunofluorescence assay market are strategically focusing on introducing fully automated solutions to maximize their market revenues. Fully automated solutions streamline the entire immunofluorescence testing process, from sample preparation to incubation, washing, and slide mounting. Revvity Inc., a US-based life sciences and diagnostics company, launched UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics in June 2023. UNIQO 160, a tabletop device, integrates automated processing with a high-quality microscope, capable of handling up to 160 main samples and 18 slides in a single run. The system utilizes barcode recognition for individual samples, reagents, and slides.

In March 2021, Fortis Life Sciences, a US-based life sciences company, acquired Bethyl Laboratories. This acquisition aims to support Bethyl Laboratories' growth through Fortis's business expertise and product line differentiation. Bethyl Laboratories is a premium antibody company based in the USA.

Major companies operating in the immunofluorescence assay market include Thermo Fisher Scientific Inc., Abcam PLC, Bio-Rad Laboratories Inc., PerkinElmer Inc., Werfen Company, Merck KGaA, Danaher Corporation, Cell Signaling Technology Inc., Vector Laboratories Inc., INOVA Diagnostics Inc., Sino Biological Inc., Medipan GmbH, BioLegend Inc., Jackson ImmunoResearch Laboratories Inc., Rockland Immunochemicals Inc., Bethyl Laboratories Inc., Fitzgerald Industries International Inc., Creative Diagnostics, Boster Biological Technology, Acris Antibodies GmbH, RayBiotech Inc., Proteintech Group Inc., Novus Biologicals LLC, R&D Systems Inc., OriGene Technologies Inc., GenScript Biotech Corporation, MBL International Corporation, Abnova Corporation, Cellabs India Technologies Limited, J. Mitra & Co. Pvt. Ltd., EpiGentek Group Inc., Elabscience Biotechnology Co. Ltd., Aesku.Diagnostics GmbH

North America was the largest region in the immunofluorescence assay market in 2023, and it is also expected to be the fastest-growing region in the forecast period. The regions covered in the immunofluorescence assay market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immunofluorescence assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

The immunofluorescence assay market consists of sales of indirect IF complement-fixation (IF-CF), and double IF. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.